September 16, 2024 09:00 AM EDTUpdated 09:24 AM
People
R&D

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

Kyle LaHucik

Senior Reporter

BARCELONA — In the span of 30 min­utes, 29-year Mer­ck vet­er­an Eli­av Barr can analo­gize drug de­vel­op­ment deal­mak­ing to Reese’s can­dy, call him­self an “old …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times